NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing researchers with advanced materials for critical scientific exploration. Today, we focus on 7-Xylosyltaxol (CAS 90332-66-4), a notable cytotoxic agent derivative that plays a crucial role in anticancer drug discovery and the study of its inherent antineoplastic activity.

As a Paclitaxel derivative, 7-Xylosyltaxol exhibits potent cytotoxic properties, making it an invaluable tool for researchers investigating novel therapeutic strategies. The study of its 7-Xylosyltaxol CAS 90332-66-4 antineoplastic activity involves understanding its interaction with cellular components, particularly microtubules, which are vital for cell division. This makes it a significant compound in the ongoing quest for more effective cancer treatments and advancements in the field of cytotoxic agents.

Our role as a manufacturer and supplier in China is to ensure that scientists have access to compounds like 7-Xylosyltaxol with the highest levels of purity and consistency. This reliability is essential for conducting meaningful research in anticancer drug discovery, where precise experimental conditions and accurate data are paramount. The price point for such specialized chemicals reflects the advanced synthesis and purification processes required.

Researchers looking to buy 7-Xylosyltaxol can leverage its properties for in-depth pharmacological investigations. Its application extends to exploring mechanisms of drug resistance, synergistic effects with other compounds, and the development of targeted therapies. By providing this critical intermediate, NINGBO INNO PHARMCHEM CO.,LTD. supports the scientific community's efforts to bring life-saving treatments from the lab to the clinic.

The ongoing exploration of cytotoxic agents like 7-Xylosyltaxol is fundamental to making progress in cancer research. We are committed to facilitating this progress by supplying essential pharmaceutical intermediates and reference materials that enable groundbreaking discoveries and contribute to the development of next-generation cancer therapies.